GlassScriptPhysician profile
Natalka D Stachiw
NPI 1619058989
$7,019.72
in general payments reported to CMS, 2019-2025
22 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what 81% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $498 · 2021: $494 · 2022: $1,004 · 2023: $1,817 · 2024: $1,512 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,972 · Travel and Lodging: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.59 |
| Travel and Lodging | $464.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $990.89 | 2020-2023 | Trudi Nav Cable |
| Aerin Medical INC. | $767.84 | 2019-2025 | |
| Smith+Nephew, INC. | $743.00 | 2019-2025 | Halo, Coblation, Tula |
| Genzyme Corporation | $609.72 | 2021-2025 | |
| Intersect Ent, INC. | $549.32 | 2019-2022 | |
| Stryker Corporation | $530.52 | 2019-2025 | Xpress Ent Dilation System, Audion Et Dilation System, Clarifix Cryotherapy Device |
| Medtronic, INC. | $435.30 | 2022-2025 | Propel, Pteye Parathyroid Detection System, Stealthstation S8 Platform |
| Optinose US, INC. | $431.52 | 2019-2024 | |
| Glaxosmithkline, LLC. | $382.95 | 2023-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $352.32 | 2019-2025 | Dupixent |
| Integra Lifesciences Corporation | $249.25 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Alk-Abello, INC | $214.86 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $149.69 | 2024-2025 | Voquezna |
| Abbvie INC. | $149.16 | 2024 | |
| Ethicon US, LLC | $121.73 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $111.00 | 2025 | Dupixent |
| Cochlear Americas | $105.27 | 2022 | |
| Neurent Medical Limited | $59.99 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Merck Sharp & Dohme LLC | $20.06 | 2023 | |
| Hikma Pharmaceuticals USA | $17.56 | 2023 | Ryaltris |
| Amgen INC. | $14.42 | 2025 | Tezspire |
| Karl Storz Endoscopy-America | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalka Stachiw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.